Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COWBOY: Vemurafenib and Cobimetinib Induction Before Ipilimumab and Nivolumab in BRAF-Mutated Melanoma
NCT02968303Phase 2Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2017
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vemurafenib and cobimetinib in melanoma (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Best Overall Response Rate at 18 weeks. Status: unknown.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02968303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968303.